Benign prostatic hyperplasia (BPH) is common among aging men. Untreated BPH may lead to complications including urinary tract infection, acute urinary retention, and obstructive nephropathy. Diagnosing BPH can be challenging because lower urinary tract symptoms are found in conditions other than BPH, and prostate size correlates poorly with symptoms of obstruction. Nonetheless, a careful medical history and physical examination, along with prudent use of diagnostic tests, can yield an accurate diagnosis. We review the evaluation of men with suspected BPH and indications for referral to a urologist for invasive therapy. We also review supporting evidence and treatment considerations for saw palmetto and the 2 major classes of prescription medications, α α α α α 1 -adrenergic antagonists and 5α α α α α-reductase inhibitors. ) in men younger than 30 years, but its size increases gradually, leading to BPH in most men older than 60 years.
B
enign prostatic hyperplasia (BPH) is common in older men. The prostate is about the size of a walnut (20 cm 3 ) in men younger than 30 years, but its size increases gradually, leading to BPH in most men older than 60 years. 1, 2 Benign prostatic hyperplasia results from the growth of epithelial and stromal cells. Hyperplasia begins in the transition zone of the prostate gland, 3 causing urinary outflow resistance. Eventually, this resistance may lead to detrusor dysfunction, bladder trabeculation, and uninhibited bladder contractions. 4 There is evidence that BPH progresses when untreated. Rhodes et al 5 showed that prostate volumes increase steadily by 1.6% per year. For 6 years, Roberts et al 6 monitored 492 men older than 40 years and showed that peak urinary flow rates declined by 2.1% per year. Jacobsen et al 7 studied 2115 men older than 40 years who experienced a gradual increase in prostate symptom severity. Furthermore, the 5-year cumulative incidence of acute urinary retention ranged from 1.6% among men aged 40 to 49 years to 10% among men aged 70 to 79 years. 8 Other complications of BPH include hypotonic bladder, hematuria from friable prostatic blood vessels, bladder calculi, urinary tract infections, and obstructive nephropathy. 4 Diagnosing BPH and determining its clinical prevalence is challenging because diagnostic criteria are not always reliable in men presenting with lower urinary tract symptoms (LUTS). Specifically, prostate size correlates poorly with LUTS, [9] [10] [11] and numerous conditions other than BPH can cause LUTS. 12, 13 Nevertheless, criteria such as symptom severity, prostatic enlargement on digital rectal examination (DRE), and abnormal results from uroflow studies with increased postvoid residual urine aid in diagnosis of BPH. 14 On the basis of clinical criteria, the Baltimore Longitudinal Study of Aging found that the prevalence of BPH is approximately 25% in men aged 40 to 49 years, 50% in men aged 50 to 59 years, and 80% in men aged 70 to 79 years. 1 Notably, the clinical prevalence of BPH generally correlates with autopsy data. 1, 2, 15 EVALUATING MEN WITH BPH MEDICAL HISTORY AND PHYSICAL EXAMINATION When obtaining a medical history, consideration of a patient's age is important. Because the prevalence of BPH increases with age, LUTS in men older than 50 years are probably due to BPH; LUTS in men younger than 40 years are usually due to other causes. 2 Review of a patient's medications is also important because many medications can cause LUTS. Examples include urinary frequency from diuretics, increased urethral sphincter contractility from sympathomimetic agents, and decreased detrusor contractility from anticholinergic medications. 16, 17 Although surprisingly little is known about the relationships between medications and BPH, 18 Su et al 19 reported that daily use of antidepressants and antihistamines is associated with increased prostate symptom scores in 40-to 79-year-old men compared with age-matched controls. Physicians also should identify use of over-the-counter medications, especially cold remedies, which can cause LUTS by various mechanisms. Indeed, men with subclinical BPH sometimes develop symptoms with initiation of a new medication. In these men, simply stopping the new medication leads to symptom resolution. Finally, a focused review of systems should be obtained to identify fever, hematuria (indicating urothelial cancer, infection, or bladder calculi), urethral instrumentation or sexually transmitted diseases (raising the possibility of urethral stricture), sleep disturbances, patterns of fluid consumption, and use of alcohol and caffeine. Lower urinary tract symptoms are divided typically into the categories of obstructive, which includes straining, hesitancy, weak stream, intermittency, and sense of incomplete bladder emptying, and irritative, which includes urgency, frequency, and nocturia. Lower urinary tract symptoms are associated with numerous medical conditions other than BPH. For this reason, a broad differential diagnosis should be considered for all patients presenting with LUTS ( Table 1) .
The American Urological Association Symptom Score (AUA-SS), otherwise known as the International Prostate Symptom Score, is an objective measurement of symptoms associated with BPH. The AUA-SS aids in diagnosis of BPH and in monitoring of patients with BPH over time (ie, in watchful waiting or in gauging therapeutic response to medical therapy). The AUA-SS is a major criterion for clinical decision making regarding the therapeutic approach to men presenting with symptoms of BPH ( Figure   1 ). 12 The AUA-SS has been tested rigorously for reliability and validity and has been shown to have good internal and test-retest reliability, strong correlation with global symptom severity, and the ability to discriminate men with BPH from controls. 20 The AUA-SS includes 7 questions representing the following symptoms: frequency, nocturia, weak stream, hesitancy, intermittency, incomplete bladder emptying, and urgency. Each of the 7 questions is rated on a 5-point Likert scale: a sum of 0 to 7 represents mild symptoms of BPH, 8 to 19 represents moderate symptoms, and 20 to 35 represents severe symptoms.
When examining patients with LUTS, evaluating for neurologic deficits is important, especially if patients have a history or presenting symptoms suggesting a neurologic disorder. In such patients, useful findings include saddle anesthesia, decreased rectal sphincter tone, absent cremasteric reflex, or lower extremity neurologic abnormalities. Examination of the abdomen may reveal masses resulting from a renal tumor or bladder distention. The penis should be examined for stricture or other pathologic findings. Treatment algorithm for benign prostatic hyperplasia (BPH) shows treatment decisions based partly on patient symptom severity as determined by the American Urological Association Symptom Score. AUA = American Urological Association; DRE = digital rectal examination; IPSS = International Prostate Symptom Score; PE = physical examination; PSA = prostate-specific antigen; PVR = postvoid residual urine; UTI = urinary tract infection. *In patients with clinically significant prostatic bleeding, a course of a 5α-reductase inhibitor may be used. If bleeding persists, tissue-ablative surgery is indicated. †Patients with at least a 10-year life expectancy for whom knowledge of the presence of prostate cancer would change management or patients for whom the PSA measurement may change the management of voiding symptoms. ‡After exhausting other therapeutic options as discussed in detail in the text. §Some diagnostic tests are used in predicting response to therapy. Pressure-flow studies are most useful in men before surgery. From J Urol, 12 with permission. When performing DRE, findings most consistent with BPH are symmetrical enlargement and firm prostate consistency, often likened to the thenar muscle or tip of the nose. In contrast, findings consistent with adenocarcinoma of the prostate are prostate asymmetry and induration or nodularity that is sometimes likened to the consistency of a knuckle or the forehead.
LABORATORY TESTING
The American Urological Association recommends routine urinalysis, 12 which can reveal pyuria and bacteriuria suggesting infection, hematuria suggesting inflammation or urothelial malignancy, or active urinary sediment suggesting postobstructive nephropathy. Optional studies include serum creatinine and prostate-specific antigen (PSA). 12 The PSA study is optional because it fails to discriminate BPH from adenocarcinoma of the prostate. 21 Nonetheless, we always inform patients that LUTS may indicate prostate cancer, and on this basis, PSA testing is offered routinely. Also, we endorse annual screening for prostate cancer with DRE and PSA testing in men aged 50 to 75 years and sometimes beyond 75 years, depending on the patient's preference and anticipated life expectancy.
Although serum PSA discriminates poorly between adenocarcinoma of the prostate and BPH, serum PSA levels correlate strongly with prostate volume in men with BPH. 22 Other causes of serum PSA elevation are prostate carcinoma, bacterial prostatitis, acute urinary retention, and prostate incision. 23 There is also evidence that serum PSA levels persist for 48 hours after ejaculation, 24 which is why some physicians recommend that patients avoid ejaculation for 2 days before undergoing DRE. Conditions generally not believed to elevate serum PSA level are routine DRE, transrectal ultrasonography without biopsy, cystoscopy, and bladder catheterization. 23 There are several ways to interpret serum PSA test results. The traditional cutoff is 4 ng/mL. 21 Because prostate volume (and thus serum PSA level) increases with age, 22 age-adjusted normal limits also are commonly used. The level of free (unbound) PSA is lower in men with adenocarcinoma of the prostate [25] [26] [27] ; hence, a low ratio of free to total PSA is more consistent with prostate carcinoma than with BPH. Finally, the PSA trend over time can be useful because a rapidly increasing PSA level is more suggestive of carcinoma than of BPH. 28 Specifically, a PSA velocity greater than 0.75 ng/mL per year is considered abnormal.
The uroflow study is an objective, noninvasive way to evaluate LUTS. An accurate study requires a urine volume of at least 150 mL. 18 Peak urinary flow rates of less than 15 mL/s and increased urine residuals often are seen in men with BPH ( Figure 2) . Importantly, abnormal results also are seen in patients with detrusor muscle dysfunction. Consequently, as with any test, interpreting the results of uroflow studies depends on the pretest probability of disease. If the pretest probability of BPH is high, then abnormal test results are useful for confirming the diagnosis. However, if the pretest probability of BPH is intermediate, then abnormal results from the uroflow study are less useful. In such cases, patients may need to undergo complete urodynamic studies to further separate BPH from other causes of LUTS.
MEDICAL MANAGEMENT OF BPH
This article focuses on the medical management of BPH, but it is important for clinicians to recognize the indications for referral to a urologist for consideration of invasive therapy. These indications are moderate to severe symptoms, persistent gross hematuria, urinary retention, renal insufficiency due to BPH, recurrent urinary tract infections, and bladder calculi. 12 Watchful waiting is a reasonable approach for patients with mild to moderate symptoms. 12 These patients are monitored at least yearly or if new symptoms arise. Also, these patients may be advised to practice scheduled voiding (every 3 hours during the day) to avoid excessive evening fluid intake, and to be aware of the potential adverse effects that over-the-counter decongestants can have on voiding.
Most patients presenting initially with BPH are candidates for medical therapy. Moreover, medical therapy has replaced interventional therapy as the most common treat-FIGURE 2. Uroflow tracing (top) from a young asymptomatic man. Note the parabolic flow curve and peak urinary flow rate of greater than 15 mL/s. This patient had 9 mL of residual urine on ultrasonography. Uroflow tracing (bottom) from an elderly man with benign prostatic hyperplasia. Note the prolonged voiding time and peak urinary flow rate of less than 10 mL/s. This patient had 100 mL of residual urine on ultrasonography. ment of BPH. 13 The categories of prescription medications currently available for treating BPH are α 1 -adrenergic antagonists (eg, tamsulosin) and 5α-reductase inhibitors (eg, finasteride). These medications act on dynamic and static components of bladder outlet obstruction. 13, 29 α 1 -Adrenergic antagonists are the initial choice of medical therapy for most men with BPH. Medications from the α 1 -adrenergic antagonist category act on the dynamic component of bladder outlet obstruction by relaxing prostate smooth muscle. A meta-analysis by Djavan and Marberger 30 reviewed the randomized controlled trials of the α 1 -adrenergic antagonists used for treatment of BPH. The authors found that, although all these medications are equally efficacious for treating BPH, terazosin and doxazosin have higher adverse effect profiles (namely, orthostatic hypotension) than do other medications from this class. Other common adverse effects of α 1 -adrenergic antagonists include dizziness, headache, nasal congestion, hypotension, edema, palpitations, erectile dysfunction (ED), and fatigue.
Because aging men make up a large proportion of the population, the prevalence and treatment of BPH and ED will increase (indeed, this fact has spawned recent research regarding the relationship between BPH and ED). 31 Therefore, it is important to recognize that combining phosphodiesterase type 5 inhibitors (eg, sildenafil) with medications from the α 1 -adrenergic antagonist class can cause profound hypotension. Recommendations regarding combinations of these medications are as follows: (1) sildenafil should not be taken within 4 hours of any α 1 -adrenergic antagonist, (2) vardenafil should not be taken with any α 1 -adrenergic antagonist, and (3) tadalafil should not be taken with any α 1 -adrenergic antagonist except tamsulosin at a 0.4-mg dose.
The second class of medications available for treatment of BPH is the 5α-reductase inhibitors, which act on the static (anatomical) component of bladder outlet obstruction. These medications work by reducing the conversion of testosterone to dihydrotestosterone (DHT) in the prostate, thereby limiting prostate growth. The 2 currently available 5α-reductase inhibitors are finasteride and dutasteride.
Numerous studies reveal the efficacy of, and guide the appropriate prescribing of, finasteride. McConnell et al 32 showed that finasteride, compared with placebo, reduces the risks of urinary retention (relative risk, 0.57; P<.001) and surgery (relative risk, 0.55; P<.001), improves urinary flow rates, and decreases prostate volume (P<.001). Results from this study also showed that 6 to 12 months of therapy may be required to see the full effect from the drug. Hence, patients are counseled that they may need to take finasteride for several months before they notice symptom improvement. Abrams et al 33 reported that outcomes with finasteride are most favorable in men with large prostate glands (>40 mL). For this reason, finasteride often is used as initial therapy for men with moderate to severe BPH. A randomized placebo-controlled trial by Gormley et al 34 showed that finasteride significantly decreased symptom scores and prostate volume and increased maximal urinary flow rates. Moreover, patients taking finasteride experienced significant reductions in serum PSA level. On this basis, experts advocate correction of the assessment of PSA level in patients taking finasteride by multiplying the PSA value by 2. 13, 35 Finasteride is well tolerated, and serious adverse effects are uncommon. The most frequent adverse effects are related to sexual dysfunction and include decreased libido, ejaculatory dysfunction, and ED. Other adverse effects include gynecomastia and orthostatic hypotension.
Dutasteride, the second medication from the 5α-reductase inhibitor class, inhibits 5α-reductase isoenzyme types 1 and 2, 36 whereas finasteride inhibits only 5α-reductase isoenzyme type 2. Likewise, clinical trials in men with BPH showed that dutasteride reduced serum DHT levels by 93%, 37 whereas finasteride reduced serum DHT levels by only 70%. 38 The safety of dutasteride was shown by a pooled analysis of 3 randomized, blinded placebo-controlled trials. In this analysis, 37 at 2-year follow-up, patients taking dutasteride experienced significant reductions in symptom scores, prostate volumes, and risk of surgical intervention. Only 1 clinical trial compared outcomes in patients taking dutasteride vs finasteride. 39 The Enlarged Prostate International Comparison Study randomized 1630 patients with BPH to either dutasteride or finasteride. 40 Study findings included no significant differences in prostate volume reduction or improvement in urinary flow rates. 39 The most common adverse effects, which did not differ significantly between intervention groups, were related to sexual dysfunction. 39 Evidence supports combining an α 1 -reductase inhibitor and a 5α-reductase inhibitor when treating BPH; in men with large prostate glands and elevated PSA levels, combination therapy should be considered the first-line approach. The Medical Therapy of Prostatic Symptoms (MTOPS) trial involved 3407 men with BPH who were randomized to placebo, doxazosin, finasteride, or combination therapy. 41 Significant findings were a 66% reduction of clinical progression with combination therapy (P<.001), a reduced risk of acute urinary retention or need for invasive therapy with combination therapy (P<.001), and improved symptom scores with invasive therapy (P<.001). However, the most remarkable finding was the low number needed to treat (8.4) to prevent 1 instance of overall clinical progression with combination therapy.
BENIGN PROSTATIC HYPERPLASIA
Herbal medicines used to treat BPH include derivatives from African star grass, African plum tree bark, rye grass pollens, stinging nettle, and cactus flower. 42 The most commonly used alternative treatment for BPH is saw palmetto (Serenoa repens). Many mechanisms for saw palmetto have been entertained, yet none are proven. 43 Saw palmetto is considered safe, and available evidence supports its effectiveness. [43] [44] [45] In a large European trial by Carraro et al, 44 1098 men were randomized to saw palmetto or finasteride. Both treatment arms experienced the same improvement in symptom scores. Furthermore, a meta-analysis by Boyle et al 45 showed that compared with placebo, saw palmetto improves peak urinary flow rates and reduces nocturia in men with BPH.
CONCLUSIONS
Benign prostatic hyperplasia is common, with clinical evidence for BPH occurring in most men older than 60 years. Although diagnosing BPH can be challenging, obtaining a medical history including an AUA-SS, performing a careful physical examination, and using urinalysis, PSA, and uroflow studies can help exclude other causes of LUTS. Before initiation of medical therapy, indications for referral to a urologist and consideration of invasive therapy should be reviewed. α 1 -Adrenergic antagonists, which act on the dynamic component of bladder outlet obstruction, are the initial choice of medical treatment in most men with BPH. However, in men with large prostate glands (>40 mL), higher PSA levels, and moderate to severe symptoms, treatment with 5α-reductase inhibitors or combination therapy should be considered. Finally, evidence supports the use of saw palmetto for treatment of BPH in men who prefer herbal therapies. 
